Squarepoint Ops LLC reduced its position in shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE)

Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcrip

Belite Bio, Inc. Sponsored ADR (BLTE) reached a significant support level, and could be a good pick

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises

Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inher

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the

Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significa

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for

Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.

Wall Street wrapped a turbulent week with a wave of upgrades and downgrades hitting energy giants, h

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy

Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug applica

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in St

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and rai

Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight an

Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript

Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Applica

Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst conse

SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in

Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio,

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises

SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C

Belite Bio (BLTE) is positioned for upside with tinlarebant, an oral therapy for Stargardt disease,

Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational

Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease dru

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and mainta

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst conse

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $